Back to Newsroom
Back to Newsroom

What Do the Clinical Updates at Achieve Life Sciences Mean for Cytisinicline

Monday, 18 March 2019 08:35 AM

NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Achieve Life Sciences, Inc. (NASDAQ: ACHV), a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.

On March 14th, the company provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results. 2018 was a remarkable year of executing on the development plan for cytisinicline as a treatment for nicotine addiction and as an aid to smoking cessation. To put this context, smoking and nicotine addiction is a third hardest addiction to treat after heroin and cocaine, which is why these are so challenging for smokers to quit.

Cytisinicline updates, potential ACHV catalysts and more in our full analyst report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/achv/

Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Find out what cytisinicline actually is in this comprehensive analyst research report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/achv/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: [email protected]

SOURCE: Traders News Source

Topic:
Investor Relations
Back to newsroom
Back to Newsroom
Share by: